REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF PATIENTS DIAGNOSED WITH CLASSICAL HODGKIN LYMPHOMA (CHL) TREATED WITH ANTI-PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US): PS1244